comparemela.com

Latest Breaking News On - Biosciences investor contact - Page 3 : comparemela.com

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted.

United statesUnited kingdomLuis sanayJeffreym daynoIdiopathic hypersomnia development program scheduled forParagon biosciencesEuropean medicines agencyDrug administrationEuropean unionZynerba pharmaceuticalsExchange commissionHarmony biosciences holdings incNet revenueFourth quarterFull yearRepresenting growth

U S FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY

/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) granted priority review for its.

United statesLuis sanayJeffreym daynoDrug administrationParagon biosciencesPrnewswire harmony biosciences holdings incExchange commissionPrescription drug user fee actBiosciences holdingsNew drug applicationChief executive officerFull prescribing informationHarmony biosciencesPlymouth meetingPrivate securities litigation reform actAnnual report

HARMONY BIOSCIENCES RECEIVES U S FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME

/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug.

Kumar budurLuis sanayDrug administrationParagon biosciencesHarmony biosciences holdings incExchange commissionHarmony biosciences holdingsOrphan drugChief medical officerHarmony biosciencesPlymouth meetingPrivate securities litigation reform actAnnual reportBiosciences media contactBiosciences investor contact

HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024

PLYMOUTH MEETING, Pa., Feb. 8, 2024 /PRNewswire/ Harmony Biosciences Holdings, Inc. today announced that it will report fourth quarter and full year 2023 financial results on Thursday, February.

Luis sanayParagon biosciencesHarmony biosciences holdings incHarmony biosciences holdingsHarmony biosciencesPlymouth meetingBiosciences investor contactBiosciences media contact

HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE

/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue.

United statesLuis sanayJeffreym daynoDrug administrationParagon biosciencesZynerba pharmaceuticalsExchange commissionPrnewswire harmony biosciences holdings incShare repurchase programPreliminary net revenueFourth quarterFull yearRepresenting growthProduct revenue projected betweenCommon stock repurchaseFourth quarter bringing

vimarsana © 2020. All Rights Reserved.